Literature DB >> 262107

Theophylline bioavailability: a comparison of the oral absorption of a theophylline elixir and two combination theophylline tablets to intravenous aminophylline.

M Fixley, D D Shen, D L Azarnoff.   

Abstract

The bioavailability of theophylline from single doses of an elixir (Elixophyllin) and two different tablet formulations, as compared to intravenous aminophylline, was studied with a crossover design in 12 normal volunteers. Both tablet formulations (Marax and Tedral) contain ephedrine. Marax contains hydroxyzine hydrochloride, and Tedral contains phenobarbital. The absorption of theophylline was most rapid from the elixir, whereas that from Marax was faster than that from Tedral. The peak concentrations of theophylline after administration of the 3 oral dosage forms were in the order, elixir greater than Marax greater than Tedral, however, the time to achieve peak concentration was highly variable and did not differ significantly among the 3 products. On the basis of area under the serum concentration-time curves, the absorption of theophylline from the elixir and from Marax was essentially complete. The area under the serum concentration curve after administration of Tedral was significantly less than that after intravenous aminophylline, elixir, and Marax; however, when the individual areas under the concentration curves were adjusted for intrasubject variation in elimination rate constant, the mean area under the concentration curve after Tedral no longer differed significantly from those of the intravenous and other two oral products. A large degree of intersubject variation in the oral absorption of theophylline was observe din this study. Therefore, in addition to the well-documented, large individual variation in the serum clearance of theophylline, intersubject differences in the absorption of the drug is another factor that complicates proper adjustment of the dose in oral theophylline therapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 262107     DOI: 10.1164/arrd.1977.115.6.955

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

1.  Lack of effect of short-term passive smoking on the metabolic disposition of theophylline.

Authors:  D T Casto; B M Schnapf; M A Clotz
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Comparative bioavailability of a microcrystalline theophylline tablet and uncoated aminophylline tablets.

Authors:  L N Sansom; R W Milne; D Cooper
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

3.  Hypothesis for the individualisation of drug dosage.

Authors:  J R Koup; C M Sack; A L Smith; M Gibaldi
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

4.  Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study.

Authors:  Y Horai; T Ishizaki; T Sasaki; K Chiba; T Suganuma; H Echizen; A Ohnishi
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Dose-dependent pharmacokinetics with single daily dose slow release theophylline in patients with chronic lung disease.

Authors:  M A Butcher; L A Frazer; H K Reddel; G E Marlin
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

6.  Evaluation of the absorption from 15 commercial theophylline products indicating deficiencies in currently applied bioavailability criteria.

Authors:  R A Upton; L Sansom; T W Guentert; J R Powell; J F Thiercelin; V P Shah; P E Coates; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1980-06

7.  Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose.

Authors:  Y Horai; T Ishizaki; T Sasaki; M Watanabe; J Kabe
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration.

Authors:  R E Vestal; K E Thummel; B Musser; G D Mercer
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

Review 9.  Pharmacokinetic drug interactions in liver disease: An update.

Authors:  Pietro Palatini; Sara De Martin
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.